ATTENTION: SARS-CoV-2 | Coronavirus

GenBio Inc. has commenced its SARS-CoV-2 R&D program; its primary focus is to develop and or repurpose a drug(s) with a view to decreasing the severity of secondary infections, particularly pneumonia-causing bacterial pathogens. The company intends to apply for emergency use authorization within six to nine months.